[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Perou, C.M., Sørlie, T., Eisen, M.B., et al. (2000) Molecular Portraits of Human Breast Tumours. Nature, 406, 747-752.
https://doi.org/10.1038/35021093
|
[3]
|
Loibl, S., Poortmans, P., Morrow, M., et al. (2021) Breast Cancer. The Lancet, 397, 1750-1769.
https://doi.org/10.1016/S0140-6736(20)32381-3
|
[4]
|
Loibl, S. and Gianni, L. (2017) HER2-Positive Breast Cancer. The Lancet, 389, 2415-2429.
https://doi.org/10.1016/S0140-6736(16)32417-5
|
[5]
|
Ross, J.S., Slodkowska, E.A., Symmans, W.F., et al. (2009) The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. Oncologist, 14, 320-368.
https://doi.org/10.1634/theoncologist.2008-0230
|
[6]
|
Brufsky, A., Lembersky, B., Schiffman, K., et al. (2005) Hormone Receptor Status Does Not Affect the Clinical Benefit of Trastuzumab Therapy for Patients with Metastatic Breast Cancer. Clinical Breast Cancer, 6, 247-252.
https://doi.org/10.3816/CBC.2005.n.027
|
[7]
|
Bardou, V.J., Arpino, G., Elledge, R.M., et al. (2003) Proges-terone Receptor Status Significantly Improves Outcome Prediction over Estrogen Receptor Status Alone for Ad-juvant Endocrine Therapy in Two Large Breast Cancer Databases. Journal of Clinical Oncology, 21, 1973-1979. https://doi.org/10.1200/JCO.2003.09.099
|
[8]
|
Howlader, N., Altekruse, S.F., Li, C.I., et al. (2014) US inci-dence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. Journal of the National Cancer Institute, 106, dju055.
https://doi.org/10.1093/jnci/dju055
|
[9]
|
Dawood, S., Broglio, K., Buzdar, A.U., et al. (2010) Prognosis of Women with Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. Journal of Clinical Oncology, 28, 92-98.
https://doi.org/10.1200/JCO.2008.19.9844
|
[10]
|
Kreutzfeldt, J., Rozeboom, B., Dey, N., et al. (2020) The Trastuzumab Era: Current and Upcoming Targeted HER2+ Breast Cancer Therapies. American Journal of Cancer Research, 10, 1045-1067.
|
[11]
|
Blackwell, K.L., Burstein, H.J., Storniolo, A.M., et al. (2012) Overall Survival Benefit with Lapatinib in Combination with Trastuzumab for Patients with Human Epidermal Growth Factor Re-ceptor 2-Positive Metastatic Breast Cancer: Final Results from the EGF104900 Study. Journal of Clinical Oncology, 30, 2585-2592.
https://doi.org/10.1200/JCO.2011.35.6725
|
[12]
|
Swain, S.M., Miles, D., Kim, S.B., et al. (2020) Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results from a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 21, 519-530. https://doi.org/10.1016/S1470-2045(19)30863-0
|
[13]
|
Mierzynska, J., Taye, M., Pe, M., et al. (2020) Refer-ence Values for the EORTC QLQ-C30 in Early and Metastatic Breast Cancer. European Journal of Cancer, 125, 69-82. https://doi.org/10.1016/j.ejca.2019.10.031
|
[14]
|
Swain, S.M., Kim, S.B., Cortés, J., et al. (2013) Per-tuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA Study): Overall Survival Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 14, 461-471. https://doi.org/10.1016/S1470-2045(13)70130-X
|
[15]
|
Johnston, S.R.D., Hegg, R., Im, S.A., et al. (2021) Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade with Lapatinib plus Trastuzumab in Combination with an Aromatase Inhibitor in Postmenopausal Women with HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of Alternative. Journal of Clinical Oncology, 39, 79-89. https://doi.org/10.1200/JCO.20.01894
|
[16]
|
Alqaisi, A., Chen, L., Romond, E., et al. (2014) Impact of Estrogen Receptor (ER) and Human Epidermal Growth Factor Receptor-2 (HER2) Co-Expression on Breast Cancer Disease Characteristics: Implications for Tumor Biology and Research. Breast Cancer Research and Treatment, 148, 437-444. https://doi.org/10.1007/s10549-014-3145-x
|
[17]
|
Marcom, P.K., Isaacs, C., Harris, L., et al. (2007) The Combination of Letrozole and Trastuzumab as First or Second-Line Biological Therapy Produces Durable Responses in a Subset of HER2 Positive and ER Positive Advanced Breast Cancers. Breast Cancer Research and Treatment, 102, 43-49.
https://doi.org/10.1007/s10549-006-9307-8
|
[18]
|
Rimawi, M.F., Mayer, I.A., Forero, A., et al. (2013) Multi-center Phase II Study of Neoadjuvant Lapatinib and Trastuzumab with Hormonal Therapy and without Chemo-therapy in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 31, 1726-1731.
https://doi.org/10.1200/JCO.2012.44.8027
|
[19]
|
Bedard, P.L., Freedman, O.C., Howell, A., et al. (2008) Overcoming Endocrine Resistance in Breast Cancer: Are Signal Transduction Inhibitors the Answer? Breast Cancer Research and Treatment, 108, 307-317.
https://doi.org/10.1007/s10549-007-9606-8
|